- MSMB Healthcare, the co-founder and
former CEO of
pharmaceutical firms Retrophin and
Turing Pharmaceuticals, and the
former CEO of start-up
software company...
- Pharmaceuticals, the DARA
programs was
licensed to
Retrophin and
developed as RES-021 in 2012.
Retrophin would then be
rebranded as
Travere Therapeutics...
-
acquisition of
three major ****ets from an
orphan drug
developer called Retrophin: an
intranasal formulation of ketamine, an
oxytocin nasal solution, and...
- drug back to
market in 2013.
Retrophin acquired Manchester in 2014 and
after Martin Shkreli was
forced out of
Retrophin, in 2014 his new company, Turing...
-
based attorney of
Martin Shkreli.
Greebel was the
outside counsel to
Retrophin Inc.,
which Shkreli co-founded. In 2017,
Greebel was
convicted of helping...
- Technologies,
Concert Pharmaceuticals, Pharm****et, and
Martin Shkreli's
Retrophin. In a 2023
speech and in his book Woke Inc.,
Ramaswamy called Shkreli...
-
Amgen to
market with the
first approval of a PCSK9 inhibitor. In 2015,
Retrophin sold a PRV to
Sanofi for
around $245 million, and
later the same year...
- set up an
account with the
Daraprim Direct program.
Presentations from
Retrophin, a
company formerly headed by
Martin Shkreli, CEO of Turing, from which...
-
Mission Pharmacal at $1.50 per pill, but in 2014 the
rights were
bought by
Retrophin,
owned by
Martin Shkreli, and the
price increased to $30 per pill for...
- 1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809.
Keown A (22
August 2019). "
Retrophin's Late-Stage PKAN Drug
Fails Against Placebo". BioSpace....
